Dyslipidaemia is common in perinatally HIV-infected (PHIV) youth receiving protease inhibitors (PIs). Few studies have evaluated longitudinal lipid changes in PHIV youth after switch to newer PIs.
Introduction
Combination antiretroviral therapy (ART) regimens, which often include protease inhibitors (PIs), have markedly advanced the treatment of HIV-infected children and adults. Since the introduction of ART, substantial declines in morbidity [1] and mortality [2] have been achieved in these individuals, although not without potentially significant side effects. Metabolic complications of HIV infection and ART, including dyslipidaemia [3, 4] , fat redistribution [5] [6] [7] , and insulin resistance [8, 9] (collectively known as the metabolic syndrome), have been documented extensively and may be the result of complex interactions between HIV infection, ART, age, race, socioeconomics, diet, and lifestyle factors [10] . As perinatally HIV-infected (PHIV) children confront the challenge of lifetime ART exposure, these metabolic disturbances are of particular concern as they may place PHIV adolescents and young adults at significantly increased cumulative cardiovascular risk over time.
The prevalence of dyslipidaemia in HIV-infected children and adolescents has been reported to be from 11 to as high as 73%, depending on specific study definitions of dyslipidaemia, sample size, and study locations worldwide [11] [12] [13] [14] [15] [16] [17] . Few studies, however, have assessed longitudinal lipid changes in the paediatric HIV-infected population during this era of newer PIs, such as atazanavir/ritonavir (ATV/r) and darunavir/ritonavir (DRV/r). The objective of our study was to evaluate whether a switch to ATV/r-or DRV/r-based ART from an older PI-based ART was associated with an improved lipid profile over time.
Materials and methods

Study population
This study included PHIV youth enrolled in the Pediatric HIV/AIDS Cohort Study (PHACS) Adolescent Master Protocol (AMP), an ongoing prospective cohort study of PHIV youth designed to evaluate the long-term impact of HIV and ART in children, adolescents, and young adults living with PHIV. PHACS AMP began enrolment of children 7-15 years of age in 2007 across 15 US sites, including Puerto Rico. For this analysis, we included PHIV youth who were receiving an ART regimen consisting of an older PI (non-ATV and non-DRV) plus nucleoside reverse transcriptase inhibitors (NRTIs) at study entry with fasting lipids measured at least once.
Exclusions included current pregnancy, known diabetes or renal disease, use of ATV or DRV prior to AMP enrolment, switch to a non-PI-based ART regimen, and switch to an ART regimen consisting of three or more classes of antiretrovirals (ARVs) [i.e. NRTI + PI + integrase strand inhibitors (INSTIs)]. Institutional review boards (IRBs) at each site approved the protocol, and informed consent was obtained from each youth's parent or legal guardian. Assent was obtained from youth participants per local IRB guidelines.
Primary exposure of interest
Switch from an older PI to either boosted ATV or DRV was considered the primary exposure of interest, and this group was compared with those who remained on an older PI ART regimen (non-ATV, non-DRV). Information on specific ARV use over time was collected longitudinally.
Primary outcomes
Outcomes of interest included the following fasting lipid subfractions: total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and the TC:HDL-C ratio. For the group who switched, lipid measures from the visit just prior to switch and then annually thereafter for 3 years were assessed. For the comparison group, lipid measures were assessed starting at the time of first fasting serum sample collection. The "baseline" time-point was defined as the date of lipid measurement just prior to switch for the former group, and at the time of first lipid measurement for the latter comparison group. Lipid testing was performed in real time at each clinical site; blood specimens were processed and analysed using standard techniques. We evaluated rates of change for lipid subfractions over time. Hypercholesterolaemia (elevated TC), hypertriglyceridaemia, and elevated LDL-C were defined as levels > 95th percentile and low HDL-C as levels < 5th percentile for age and sex by US standards [18, 19] .
Covariates
Information on potential confounders including age, sex, race/ethnicity, Tanner stage, anthropometrics, and HIV disease parameters was collected. Body mass index (BMI) and waist circumference were measured in standardized fashion [20] , and BMI z scores (BMIZ) were calculated from Centers for Disease Control and Prevention (CDC) 2000 Growth Standards [21] . Blood pressure at baseline was measured and categorized as pre-hypertension if either the systolic or diastolic blood pressure exceeded the 90th percentile for age, sex and height according to US National High Blood Pressure Education Program Working Group on Children/Adolescents [22] . HIV CD4 cell count and HIV RNA level at baseline were collected via medical record review.
Statistical analysis
With the sample size obtained in our analysis, we had > 80% power to detect a difference in the change in lipid outcomes of 20 mg/dL for TC, 15 mg/dL for LDL-C, 5 mg/dL for HDL-C and 35 mg/dL for TG. Baseline characteristics in those who switched to ATV/r or DRV/r and those who remained on an older PI were compared using Student's t-test or Wilcoxon rank sum test for continuous variables and v 2 or Fisher's exact test for categorical variables, as appropriate. Local weighted scatter-plot smoothing (LOESS) plots were fitted to describe longitudinal changes in each mean lipid subfraction over time. Generalized estimating equation (GEE) linear regression models were fitted to assess the association of a switch to ATV/r or DRV/r-based ART with the average annual rate of change in each lipid subfraction, adjusted for potential confounders. Correlations between repeated lipid measures over time in the same participant were accounted for using an autoregressive assumption. Thus, each model had a main effect for treatment group (switch vs. no switch), time since baseline and each confounder variable, and an interaction term for treatment group by time. We employed an interaction term to test for differences in the rate of change of the lipid outcome between those who switched to ATV/DRV and those who did not switch. Analyses were performed to compare baseline characteristics of those lost to follow-up vs. those not lost to follow-up. Subgroup analyses restricted to those without hypertriglyceridaemia at baseline were conducted to evaluate changes in triglycerides. Statistical analyses were performed using SAS â 9.4 (SAS Institute, Cary, NC, USA).
Results
From 2007 to 2014, 47 PHIV youth switched to ATV/r (n = 27) or DRV/r (n = 20) while 120 remained on an older PI (Table 1) . Of the latter, 72% received lopinavir/r, 24% nelfinavir, and 2% fosamprenavir/r. The majority of NRTI backbones at baseline included zidovudine/lamivudine (20%), tenofovir/emtricitabine (20%), abacavir/lamivudine or abacavir/lamivudine/zidovudine (19%), or stavudine/ lamivudine (14%). Baseline age ranged from 7 to 21 years, with 73% non-Hispanic black. At baseline, PHIV youth in the switch group were older than those in the nonswitch group (median age 14.6 vs. 11.5 years, respectively; P < 0.001), reported more years of having been on ART (11.9 vs. 8.3 years, respectively; P < 0.001), and were less likely to be Tanner stage 1 (6 vs. 34%, respectively; P < 0.001). At baseline, those in the switch group also had lower TC than those in the nonswitch group (158 vs. 177 mg/dL, respectively; P = 0.042) and lower HDL-C (45 vs. 51 mg/dL, respectively; P = 0.021). There were no differences between groups in race/ethnicity, or in baseline BMI z score, CD4 cell count, HIV RNA level, or rates of hypercholesterolaemia, hypertriglyceridaemia, elevated LDL-C, or low HDL-C. The overall rate of hypercholesterolaemia was 12%, that of hypertriglyceridaemia was 43%, that of elevated LDL-C was 14%, and that of low HDL-C was 4%. The median (range) follow-up time was 1.9 (0-3) vs. 2.0 (0-3) years, and the median (range) number of visits with lipid assessments was 3 (1-4) and 3 (1-5) in the switch and nonswitch groups, respectively. No significant differences in baseline characteristics were found between those who were lost to follow-up and those who were not lost to follow-up. Figure 1 shows plots of mean TC, TG, HDL-C, LDL-C, and TC:HDL-C ratio over time by PI treatment group. After adjusting for baseline age, Tanner stage, race/ethnicity, and HIV RNA level, switch to ATV/r or DRV/r was associated with a greater rate of decline in the ratio of TC:HDL-C (b = À0.12 per year; P = 0.039) over time. On average, TC declined by 4.57 mg/dL/year (P = 0.057) more in the switch group (Table 2) . There was no association between a switch to ATV/r or DRV/r and the rate of increase in HDL-C or decline in LDL-C or TG. However, in subgroup analyses restricted to youth without hypertriglyceridaemia at baseline (n = 96), TG declined on average by 7.78 mg/dL/year (P = 0.051) more in the switch group, and this relationship persisted even after adjusting for confounders (average decline = 7.15 mg/dL/ year more in the switch group; P = 0.061).
Discussion
In the PHACS AMP cohort of PHIV youth, we found that a switch to ATV/r or DRV/r from older PIs resulted in more pronounced declines in TC and TC:HDL-C ratio over time compared with the values for those who remained on older PIs. Our results are consistent with those of studies in treatment-na€ ıve HIV-infected adults, which have shown improved metabolic parameters with newer PIs [23] [24] [25] [26] . Few studies, however, have been published in the paediatric HIV-infected population on longitudinal lipid changes over time with newer PIs such as ATV/r and DRV/r, and most have been limited by small sample sizes [27] [28] [29] . Similar to our findings, a case series of HIV-infected children who switched from lopinavir/r to ATV/r or DRV/r reported a significant reduction in TC at 18 months post switch compared with baseline levels, but no changes in TG, HDL-C or LDL-C [29] . Children in the Darunavir EvaLuation in Pediatric, HIVInfected, treatment-experienced patients (DELPHI) trial begun on darunavir demonstrated decreases in TG levels 48 weeks post-initiation [27] . The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) 1020 protocol reported an increase in rates of hypercholesterolaemia (TC ≥ 200 mg/dL) from 1 to 5.7% and a decrease in rates of hypertriglyceridaemia (TG ≥ 150 mg/dL) from 26 to 14% among treatment-na€ ıve and -experienced children initiating ATV alone or ATV/r in an open-label study at 48 weeks post-initiation [28] .
Associations between ART use and dyslipidaemia have been confirmed in several cross-sectional [12, 13, 30, 31] as well as longitudinal [4, [32] [33] [34] [35] paediatric HIVinfected cohorts. Longitudinal studies in children with All categorical variables are expressed as n (%). All continuous variables are expressed as median (interquartile range) except z scores and log10 HIV RNA level, which are expressed as mean (standard deviation). P-values are from Student's t-test, the Wilcoxon test, the c 2 test or Fisher's exact test, as appropriate. ART, antiretroviral therapy; ATV/r, atazanavir/ritonavir; BMI, body mass index; d4T, stavudine; ddI, didanosine; DRV/r, darunavir/ritonavir; HDL-C, highdensity lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; PI, protease inhibitor; TC, total cholesterol. HIV infection have reported associations of dyslipidaemia with BMI [32] , Tanner stage [33] , longer duration of ART [34] , HIV RNA level < 400 copies/mL [17] , and PI use [4, 32, 33, 35] . However, PI use in these studies was limited to older non-ATV and non-DRV PIs. Some studies have evaluated lipid changes after switch or initiation of ART during an era of older PIs [6, 17, 36] . One study in South Africa reported lower mean HDL-C and higher mean LDL-C, TG, and TC:HDL-C ratio in a group of HIVinfected children randomized to lopinavir/ritonavir (PI) vs. those remaining on nevirapine [6] . The Pediatric AIDS Clinical Trials Group (PACTG) 1010 evaluated HIVinfected children initiating PI-based ART or switching to PI plus nonnucleoside reverse transcriptase inhibitor (NNRTI) ART as a consequence of virological failure and found an association between PI + NNRTI-based ART and increased TC:HDL-C ratio as well as increased TG level [17] .
Dyslipidaemia is known to be associated with cardiovascular disease in adults [37] . Children with dyslipidaemia as young as age 5-10 years are likely to have it as adults, with this correlation between childhood and adulthood dyslipidaemia being even more pronounced in obese individuals [38] . Current American College of Cardiology (ACC) and American Heart Association (AHA) guidelines on cardiovascular risk assessment recommend use of a risk calculator which factors in several variables, including age, race, TC, HDL-C, systolic blood pressure, treatment for hypertension, diabetes, and smoking [39] . Optimal TC levels are defined as < 170 mg/dL, for children and adolescents [38] . In addition, the Pathological Determinants of Atherosclerosis in Youth (PDAY) study demonstrated that each 30 mg/dL increment in non-HDL-C cholesterol (TC minus HDL-C) corresponded to approximately 2 years of vascular aging [40] . In PHIV children on lifelong ART with a risk for metabolic complications, a switch to a newer PI, such as ATV/r or DRV/r in our study, could decrease TC by 30 mg/dL up to five times faster compared with older PIs, potentially decreasing atherosclerotic risk significantly before reaching adulthood. We also observed a more pronounced rate of decline in TC:HDL-C ratio with a switch to ATV/r or DRV/r, probably as a result of the effect on TC, as differences in the rate of change of HDL-C over time were not noted between groups. The TC:HDL-C ratio has been shown to have higher discriminatory power in assessing cardiovascular disease risk than either measurement alone [41] . Lastly, the more rapid decline in TG we found with a switch to ATV/r or DRV/r among those with normal TG at baseline highlights further potential beneficial effects on lipids in PHIV youth receiving newer compared with older PIs.
Current US 2017 Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection recommend lopinavir/r as part of preferred initial ART regimens for children ≥ 14 days to < 3 years of age [42] . World Health Organization (WHO) 2016 Guidelines currently recommend lopinavir/r as the first choice for second-line ART in children, with ATV/r recommended only as an alternative second-line ART and DRV/r recommended only in special situations. Among adolescents, the first choice for second-line ART remains lopinavir/r or ATV/r, with DRV/ r only as alternative second-line ART [43] . In subSaharan Africa, where the overwhelming majority of HIV-infected youth reside, the mainstay of second-line ART remains lopinavir/r for this population despite its poorer metabolic risk profile. In addition to the global burden of HIV disease in sub-Saharan Africa, the number of deaths there from cardiovascular disease increased 81% between 1990 and 2013 [44] , raising concern that metabolic complications from HIV infection and ART, specifically older PIs such as lopinavir/r, may compound an increasing risk for cardiovascular disease worldwide and in low-and middle-income countries. Switch to ATV/r-or DRV/r-based ART in lieu of lopinavir/r could potentially help modify cardiovascular disease risk early in life in the paediatric HIV-infected population. Our study was limited by its observational design, in that there may be unmeasured confounding of exposureoutcome relationships. However, no randomized controlled trials exist to date comparing older PIs and ATV/r or DRV/r in children. Because of the observational design, we were also unable to disentangle any potential effect of NRTI therapy from the switch in PI treatment. However, consistent with evolving paediatric HIV treatment guidelines, participants in both PI treatment groups underwent similar changes in the NRTI backbone over time, with the vast majority of changes resulting in discontinuation of older NRTIs and initiation of newer NRTIs. In addition, well over half of participants receiving stavudine had this discontinued throughout the course of longitudinal follow-up.
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